Compare ABAT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABAT | CLLS |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.2M | 384.3M |
| IPO Year | 2013 | 2014 |
| Metric | ABAT | CLLS |
|---|---|---|
| Price | $3.17 | $4.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 4.1M | 26.0K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.40 | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $1.33 |
| 52 Week High | $11.49 | $5.48 |
| Indicator | ABAT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 51.04 |
| Support Level | $3.17 | $3.39 |
| Resistance Level | $3.72 | $4.54 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 18.97 | 40.46 |
American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. Additionally, the company advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company's activities focus on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.